On July 16, 2025 Amphista Therapeutics ("the Company" or "Amphista"), a leader in the discovery of next-generation, Targeted Protein Degradation (TPD) medicines, reported the successful achievement of a discovery research milestone under its exclusive research collaboration and licence agreement with Merck (Press release, Amphista Therapeutics, JUL 16, 2025, View Source [SID1234654404]). In conjunction with the milestone achievement, Amphista receives a pre-specified financial payment. The associated target on which the milestone is triggered is currently undisclosed.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"As we continue to build our portfolio of first- and/or best-in-class Targeted Glues, we are delighted to have reached an important milestone in our collaboration with Merck. The progress we have made together speaks to the effective partnership between scientists from both companies, enabling us to focus on advancing high-quality compounds for further development," said Antony Mattessich, Chief Executive Officer at Amphista. "This achievement reinforces the exceptional capabilities of our Eclipsys platform in the rational design of orally bioavailable protein degraders, bringing us a step closer to improving patient outcomes."

Under the agreement, Amphista is responsible for the discovery and early development of small molecule protein degraders using its Eclipsys platform. Merck is granted a global exclusive license to the resulting degrader molecules and will be responsible for further development and commercialisation activities.